Cargando…

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells

Numerous hematologic neoplasms, including acute B-lymphoblastic leukemia (B-ALL), are characterized by overexpression of anti-apoptotic BCL-2 family proteins. Despite the high clinical efficacy of the specific BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) and chronic lymphocytic leukemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holz, Clemens, Lange, Sandra, Sekora, Anett, Knuebel, Gudrun, Krohn, Saskia, Murua Escobar, Hugo, Junghanss, Christian, Richter, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865387/ https://www.ncbi.nlm.nih.gov/pubmed/36674872 http://dx.doi.org/10.3390/ijms24021359

Ejemplares similares

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
por: Roolf, C., et al.
Publicado: (2018)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models
por: Richter, Anna, et al.
Publicado: (2022)

Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation
por: Peters, Sabrina, et al.
Publicado: (2016)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2019)

Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania
por: Grunwald, Luise, et al.
Publicado: (2020)

Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells
por: Roolf, Catrin, et al.
Publicado: (2019)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

B‐cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement
por: Kemps, Paul G., et al.
Publicado: (2020)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Spirooxindol‐1,3‐oxazine Alkaloids: Highly Potent and Selective Antitumor Agents Evolved from Iterative Structure Optimization
por: Eichhorst, Annika, et al.
Publicado: (2022)

Polymorphisms of the murine mitochondrial ND4, CYTB and COX3 genes impact hematopoiesis during aging
por: Kretzschmar, Christin, et al.
Publicado: (2016)

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
por: Marco-Ayala, Javier, et al.
Publicado: (2020)

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines
por: Liu, Wen, et al.
Publicado: (2020)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
por: Louzada-Neto, Orlando, et al.
Publicado: (2020)

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements
por: Wen, Jinquan, et al.
Publicado: (2022)

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Eadie, Laura N., et al.
Publicado: (2023)

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
por: Cheung, Laurence C., et al.
Publicado: (2022)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
por: Kretzschmar, Christin, et al.
Publicado: (2014)

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach
por: Sender, Sina, et al.
Publicado: (2022)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
por: Stutterheim, Janine, et al.
Publicado: (2021)

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia
por: Khabirova, Eleonora, et al.
Publicado: (2022)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
por: Fukushima, Hiroko, et al.
Publicado: (2017)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q42490hv9o2vntq4iusmknigse